ChiCTR2500100753 版本V1.0 版本创建时间2025/04/15 09:39:52 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2500100753 

最近更新日期:

Date of Last Refreshed on:

2025-04-15 09:39:33 

注册时间:

Date of Registration:

2025-04-15 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

阿替卡因肾上腺素注射液辅助麻醉在下颌阻生第三磨牙拔除术中对术后疼痛和肿胀的影响

Public title:

Effect of articaine hydrochloride and epinephrine tartrate injection assisted anesthesia on pain and swelling following mandibular impacted third molar extraction

注册题目简写:

English Acronym:

研究课题的正式科学名称:

阿替卡因肾上腺素注射液辅助麻醉在下颌阻生第三磨牙拔除术中对术后疼痛和肿胀的影响

Scientific title:

Effect of articaine hydrochloride and epinephrine tartrate injection assisted anesthesia on pain and swelling following mandibular impacted third molar extraction

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

傅瑜 

研究负责人:

傅瑜 

Applicant:

Fu Yu 

Study leader:

Fu Yu 

申请注册联系人电话:

Applicant telephone:

+86 178 6048 8621

研究负责人电话:

Study leader's
telephone:

+86 178 6048 8621

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

2935843647@qq.com

研究负责人电子邮件:

Study leader's E-mail:

2935843647@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

江苏省南京市鼓楼区上海路1号

研究负责人通讯地址:

江苏省南京市鼓楼区上海路1号

Applicant address:

No. 1 Shanghai Road, Gulou District, Nanjing, Jiangsu

Study leader's address:

No. 1 Shanghai Road, Gulou District, Nanjing, Jiangsu

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

南京医科大学附属口腔医院

Applicant's institution:

Affiliated Stomatological Hospital of Nanjing Medical University

研究负责人所在单位:

南京医科大学附属口腔医院

Affiliation of the Leader:

Affiliated Stomatological Hospital of Nanjing Medical University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

南医口院伦审-PJ2025-020-01

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

南京医科大学口腔医院伦理委员会

Name of the ethic committee:

The Ethical Committee Department, Affiliated Hospital of Stomatology, Nanjing Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2025-02-28 00:00:00

伦理委员会联系人:

王娟

Contact Name of the ethic committee:

Wang Juan

伦理委员会联系地址:

江苏省南京市鼓楼区上海路1号

Contact Address of the ethic committee:

No. 1 Shanghai Road, Gulou District, Nanjing, Jiangsu

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 180 6149 9518

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

南京医科大学附属口腔医院

Primary sponsor:

Affiliated Stomatological Hospital of Nanjing Medical University

研究实施负责(组长)单位地址:

江苏省南京市鼓楼区上海路1号

Primary sponsor's address:

No. 1 Shanghai Road, Gulou District, Nanjing, Jiangsu

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

江苏省

市(区县):

南京

Country:

China

Province:

Jiangsu

City:

Nanjing

单位(医院):

南京医科大学附属口腔医院

具体地址:

江苏省南京市鼓楼区上海路1号

Institution
hospital:

Affiliated Stomatological Hospital of Nanjing Medical University

Address:

No. 1 Shanghai Road, Gulou District, Nanjing, Jiangsu

经费或物资来源:

自筹

Source(s) of funding:

self-finance

研究疾病:

下颌阻生第三磨牙  

Target disease:

mandibular impacted third molar

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

研究阿替卡因肾上腺素注射液辅助麻醉在下颌阻生第三磨牙拔除术中对术后疼痛和肿胀的影响。  

Objectives of Study:

To investigate the effect of articaine hydrochloride and epinephrine tartrate injection assisted anesthesia on pain and swelling following mandibular impacted third molar extraction.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.年龄18-45岁,性别不限。 2.下颌第三磨牙阻生需要拔除者。 3.术前7天手术部位没有炎症、感染和疼痛。 4.能配合试验,签署知情同意书。

Inclusion criteria

1. Age: 18–45 years old, gender unlimited. 2. Mandibular third molar teeth affected need to be removed. 3. There was no inflammation, infection, or pain at the surgical site 7 days before surgery. 4. Can cooperate with the test and sign the informed consent.

排除标准:

1.处于急性炎症期的患牙。 2.患有糖尿病、心脏病等全身系统疾病未得到控制者。 3.口腔或颌骨内有良/恶性肿瘤者。 4.精神异常无正常行为能力。 5.局麻药物过敏。 6.正在参加其他临床试验者。 7.邻牙有牙周炎、龋坏或根尖周炎。 8.1周内服用过止痛药、抗炎药、抗抑郁药、皮质类固醇等药物。 9.术后感染。

Exclusion criteria:

1. The affected tooth is in the acute inflammatory stage. 2. Patients with uncontrolled systemic diseases, such as diabetes and heart disease. 3. There are benign or malignant tumors in the mouth or jaw. 4. Mental abnormality without normal behavioral capacity. 5. Allergy to local anesthetic drugs. 6. Currently participating in other clinical trials. 7. Periodontitis, caries, or periapical periodontitis in the adjacent teeth. 8. Have taken painkillers, anti-inflammatory drugs, antidepressants, corticosteroids, or other medications within the past week. 9. Postoperative infection.

研究实施时间:

Study execute time:

From 2025-04-20 00:00:00 To 2027-04-20 00:00:00  

征募观察对象时间:

Recruiting time:

From 2025-04-20 00:00:00 To 2027-04-20 00:00:00

干预措施:

Interventions:

组别:

术前注射阿替卡因肾上腺素注射液组

样本量:

65

Group:

The preoperative inject articaine hydrochloride and epinephrine tartrate injection group

Sample size:

干预措施:

利多卡因阻滞麻醉+阿替卡因肾上腺素注射液局部浸润麻醉后手术

干预措施代码:

Intervention:

The surgery was performed after lidocaine block anesthesia and local infiltration anesthesia with articaine hydrochloride and epinephrine tartrate injection.

Intervention code:

组别:

术后追加阿替卡因肾上腺素注射液组

样本量:

65

Group:

The postoperative inject articaine hydrochloride and epinephrine tartrate injection group

Sample size:

干预措施:

利多卡因阻滞麻醉后手术+术后即刻追加阿替卡因肾上腺素注射液。

干预措施代码:

Intervention:

Lidocaine block anesthesia after surgery, followed immediately by the addition of articaine hydrochloride and epinephrine tartrate injection.

Intervention code:

组别:

空白对照组

样本量:

65

Group:

The blank control group

Sample size:

干预措施:

常规利多卡因阻滞麻醉后手术

干预措施代码:

Intervention:

The surgery was performed after routine lidocaine block anesthesia.

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

江苏 

市(区县):

南京 

Country:

China

Province:

Jiangsu

City:

Nanjing

单位(医院):

南京医科大学附属口腔医院 

单位级别:

三甲 

Institution
hospital:

Affiliated Stomatological Hospital of Nanjing Medical University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

疼痛值

指标类型:

主要指标

Outcome:

Pain level

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肿胀值

指标类型:

主要指标

Outcome:

Swelling score

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

止痛药服用数量

指标类型:

次要指标

Outcome:

Number of painkillers taken

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

满意度评分

指标类型:

次要指标

Outcome:

Satisfaction score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 45 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

由第三方手术助手采用分段 (或分层) 随机化分组法将被纳入本研究的患者随机分为术前注射阿替卡因肾上腺素注射液组、术后追加阿替卡因肾上腺素注射液组和空白对照组三个分组。

Randomization Procedure (please state who generates the random number sequence and by what method):

The patients included in this study were randomly divided into three groups by a third-party surgical assistant using a stratified randomization method: the group injected with articaine epinephrine before surgery, the group supplemented with articaine epinephrine after surgery, and the blank control group.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

采用双盲法,对患者与资料收集人员设盲。

Blinding:

The double-blind method was used to blind patients and data collectors.

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

研究结束后6个月内,数据上传至临床试验公共管理平台,http://www.medresman.org.cn

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Within 6 months after the end of the study, clinical trials data uploaded to public management platform, http://www.medresman.org.cn

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form, CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2025-04-15 09:39:33